Brett Swansiger Hired As Chief Commercial Officer at DxTerity

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Brett Swansiger has been hired to serve as Chief Commercialization Officer. As Chief Commercial Officer and SVP of Managed Care, Brett will be responsible for building DxTerity’s US market position by identifying, developing, and negotiating strategic business partnerships with life-science organizations as well as establishing government and commercial payer contracts for DxTerity testing. This includes establishing strategic alliances, companion diagnostic development programs, intellectual property (in/out) licensing, and joint ventures that fit within DxTerity’s overall corporate strategy.

Brett brings over 20 years of commercial leadership, international business development, and managed care contracting experience within the molecular diagnostics and pharmaceutical industries. Prior to joining DxTerity, Brett held multiple commercial leadership positions at MDxHealth Inc., a multi-national urologic oncology company, including VP of Managed Care and Payer Strategy, SVP International Business Development & European Sales, and SVP of US Sales & Integrated Healthcare Systems. Brett has had significant success with establishing licensing and clinical study contracts with diagnostic and pharmaceutical market leaders as well as getting key integrated healthcare systems like Kaiser Permanente, the Veteran’s Administration, the Department of Defense, and Geisinger to adopt new molecular diagnostic testing pathways. Prior to joining MDxHealth, Brett was Vice President of Managed Care and Asia Market Access for Agendia Inc., and he held multiple commercial leadership positions at Prometheus Laboratories Inc., a Nestlé Health Science company that focuses on personalized medicine for autoimmune disorders.

“We are excited to have Brett on board. Over the last year, DxTerity has made tremendous progress in bridging the power of precision medicine to autoimmune disease. Our type 1 interferon (IFN-1) test for systemic lupus erythematous (SLE), the most common form of lupus, has been shown to be a significant predictor of a patient’s risk of developing lupus nephritis (p=0.0008) and it is being used extensively by pharmaceutical companies in clinical trials. The IFN-1 test is now available for patient use, and Brett’s experience with obtaining reimbursement and contracting with manage care organizations will play a pivotal role in this testing being adopted by the medical community across the US,” according to Bob Terbrueggen, Founder and CEO of DxTerity Diagnostics.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.